In the FLAURA2 trial (NCT04035486), first-line osimertinib plus platinum–pemetrexed significantly improved PFS and overall survival (OS) compared with osimertinib alone [17], while the MARIPOSA trial (NCT04487080) demonstrated improved PFS with lazertinib (another third-gen TKI) plus amivantamab (EGFR/MET antibody) in untreated EGFR-mutant advanced NSCLC [18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.